'HR Excellence in Research' logo awarded to institutions actively implementing the European Charter and Code for Researchers.
Please note that the job is no longer active!
A number of mAbs have been approved by regulatory agencies for in vivo diagnosis and treatments of cancer. Many of these mAbs display great therapeutic potential by inhibiting cell proliferation or as vehicles for the targeting of radionuclides and cytotoxic agents. The main pitfalls of the use of conventional mAbs in cancer diagnosis and therapy, are the immune response to non-human Abs and the mAbs large size, which impeding penetration into the tumor mass. In this context the human single-chain antibody fragments (scFvs), can be safe, poorly immunogenic, selective and effective diagnostic and therapeutic tools. The aim of this project will be to perform the in vitro and in vivo studies to determine the biological activity of scFvs, pharmacokinetic and biodistribution properties and toxic effects.
Please note that the full description may be available in the national language since some job boards have their own publication policy. Thank you for your understanding!
To better plan and organise their stay in a foreign European country, researchers and their families can also benefit of the free and personalised assistance offered by the EURAXESS Services Centres, a network of more than 200 centres located in 40 different European countries.